Optimax Holdings Bhd (XKLS:0222) Research & Development: RM0.0 Mil (TTM As of Mar. 2026)


XKLS:0222 Optimax Holdings Bhd XKLS:0222
71 GF Score
Price RM0.53
GF Value RM0.76
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Optimax Holdings Bhd Research & Development?

Optimax Holdings Bhd XKLS:0222 71 Research & Development is RM0.0 Mil as of Mar. 2026. GuruFocus rates XKLS:0222 with a GF Score™ of 71/100 and a GF Value™ of RM0.76 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Optimax Holdings Bhd's Research & Development for the three months ended in Mar. 2026 was RM0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.0 Mil.

Optimax Holdings Bhd  (XKLS:0222) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Optimax Holdings Bhd Research & Development Related Terms

Optimax Holdings Bhd Research & Development Historical Data

* Premium members only.

The historical data trend for Optimax Holdings Bhd's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Optimax Holdings Bhd Research & Development Chart

Optimax Holdings Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Optimax Holdings Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XKLS:0222
71GF Score
Optimax Holdings Bhd XKLS:0222
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Optimax Holdings Bhd Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of RM0.0 Mil mean?
Optimax Holdings Bhd (XKLS:0222) has a Research & Development of RM0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Optimax Holdings Bhd and its competitors.
Is Optimax Holdings Bhd's Research & Development too high?
Optimax Holdings Bhd's current Research & Development is RM0.0 Mil. Overall, Optimax Holdings Bhd has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Optimax Holdings Bhd's Research & Development compare to HCA and THC?
Optimax Holdings Bhd's Research & Development of RM0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Optimax Holdings Bhd and its competitors. Optimax Holdings Bhd's current Research & Development is RM0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optimax Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Optimax Holdings Bhd (XKLS:0222) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.76, compared to a current price of RM0.53 — trading 30.9% below its estimated fair value. The current Research & Development is RM0.0 Mil. Optimax Holdings Bhd's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Optimax Holdings Bhd (XKLS:0222), the current Research & Development is RM0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Optimax Holdings Bhd (XKLS:0222) Overvalued in 2026?

Based on GuruFocus' analysis, Optimax Holdings Bhd stock appears to be undervalued. The current stock price of RM0.53 is trading 30.9% below its estimated GF Value™ of RM0.76. GuruFocus considers Optimax Holdings Bhd to be Significantly Undervalued.

Key valuation signals for XKLS:0222:

  • Research & Development: RM0.0 Mil
  • GF Value™: RM0.76 vs. price of RM0.53 (30.9% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the XKLS:0222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Optimax Holdings Bhd Business Description

Address No. 145, Jalan Radin Bagus, 1st and 2nd Floor, Seri Petaling, Wilayah Persekutuan, Kuala Lumpur, SGR, MYS, 57000
Optimax Holdings Bhd is a provider of eye specialist services. The company offers a range of services with in-house medical ophthalmology at specialist centres such as specialist clinics, ambulatory care centres, satellite clinics, and specialist hospitals. The company's ambulatory care centres and specialist hospital are equipped with eye operation theatres, and procedure rooms, general and day care wards, and relevant equipment for surgical procedures. It derives revenue from refractive surgery, treatment of eye diseases and disorders, consultation and dispensary services, oculoplastic surgery, plastic Surgery and aesthetic Services and related services. The company operates in geographical segments such as: North Malaysia, Central Malaysia, South Malaysia, East Malaysia and Cambodia.
71GF Score

Get the complete analysis for XKLS:0222

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.53
Price
RM0.76
GF Value